Suppr超能文献

更高的免疫细胞辐射剂量与局部晚期食管鳞状细胞癌患者的辐射诱导性淋巴细胞减少和预后不良相关。

Higher radiation dose on immune cells is associated with radiation-induced lymphopenia and worse prognosis in patients with locally advanced esophageal squamous cell carcinoma.

机构信息

Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.

出版信息

Front Immunol. 2023 May 8;14:1066255. doi: 10.3389/fimmu.2023.1066255. eCollection 2023.

Abstract

BACKGROUND

To explore the effective dose to immune cells (EDIC) for better prognosis while avoiding radiation-induced lymphopenia (RIL) in patients with locally advanced esophageal squamous cell carcinoma (ESCC).

MATERIALS AND METHODS

Overall, 381 patients with locally advanced ESCC receiving definitive radiotherapy with or without chemotherapy (dRT ± CT) between 2014 and 2020 were included in this study. The EDIC model was calculated by radiation fraction number and mean doses to the heart, lung, and integral body. The correlation between EDIC and clinical outcomes was analyzed using Cox proportional hazards regression, and risk factors for RIL were determined by logistic regression analysis.

RESULTS

The median EDIC was 4.38 Gy. Multivariate analysis revealed that low-EDIC significantly improved the OS of patients when compared with high-EDIC (HR = 1.614, P = 0.003) and PFS (HR = 1.401, P = 0.022). Moreover, high-EDIC was associated with a higher incidence of grade 4 RIL (OR = 2.053, P = 0.007) than low-EDIC. In addition, we identified body mass index (BMI), tumor thickness, and nodal stage as independent prognostic factors of OS and PFS, while BMI (OR = 0.576, P = 0.046) and weight loss (OR = 2.214, P = 0.005) as independent risk factors of grade 4 RIL. In subgroup analyses, the good group had better clinical outcomes than the remaining two groups (P< 0.001).

CONCLUSION

This study demonstrated that EDIC significantly correlates with poor clinical outcomes and severe RIL. Optimizing treatment plans to decrease the radiation doses to immune cells is critical for improving the outcomes.

摘要

背景

为了在避免局部晚期食管鳞癌(ESCC)患者放疗所致淋巴细胞减少症(RIL)的同时,探索改善预后的免疫细胞有效剂量(EDIC)。

材料与方法

本研究纳入了 2014 年至 2020 年间接受根治性放疗(dRT)±化疗(dRT±CT)的 381 例局部晚期 ESCC 患者。通过放射分次数和心脏、肺和全身的平均剂量计算 EDIC 模型。采用 Cox 比例风险回归分析 EDIC 与临床结局的相关性,采用逻辑回归分析确定 RIL 的危险因素。

结果

中位 EDIC 为 4.38 Gy。多变量分析显示,与高 EDIC 相比,低 EDIC 显著改善了患者的总生存期(HR=1.614,P=0.003)和无进展生存期(HR=1.401,P=0.022)。此外,高 EDIC 与 4 级 RIL 的发生率较高相关(OR=2.053,P=0.007)。此外,我们确定了体重指数(BMI)、肿瘤厚度和淋巴结分期是 OS 和 PFS 的独立预后因素,而 BMI(OR=0.576,P=0.046)和体重减轻(OR=2.214,P=0.005)是 4 级 RIL 的独立危险因素。在亚组分析中,良好组的临床结局优于其余两组(P<0.001)。

结论

本研究表明,EDIC 与不良临床结局和严重 RIL 显著相关。优化治疗计划以减少免疫细胞的辐射剂量对于改善预后至关重要。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5227/10200938/c37174cd2b65/fimmu-14-1066255-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验